Tau Therapeutics, LLC Completes Phase 1 Clinical Trial of Mibefradil for Use in Oncology
Published: Jan 03, 2013
CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--JPMorgan Healthcare Conference Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for use in the treatment of solid tumors, announced today that it has completed a Phase 1 trial in normal healthy volunteers with its novel repositioned drug for use in cancer therapy, mibefradil. The 30-patient dose escalation trial evaluated the detailed pharmacokinetics of mibefradil administered four times a day and confirmed its safe dose levels for use in a Phase 1b trial. Tau concluded the trial prior to reaching a dose limiting toxicity when pharmacokinetic data demonstrated that the study reached plasma concentrations of mibefradil in humans equal to the concentrations found to be effective in pre-clinical xenograft models.